Symbols

CRVS

Corvus·NASDAQ

--(--)

CRVS fundamentals

CRVS Q4 2025 Earnings

Corvus (CRVS) released its earnings on Mar 12, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.15 (YoY +16.67%), missed estimates.

Revenue / YoY

EPS / YoY

-0.15

+16.67%

Report date

Mar 12, 2026

CRVS Earnings Call Summary for Q4,2025

Financial Strength: $246M cash post-January offering, extending runway to Q2 2028.
Socolitinib AD Breakthrough: 72% EASI-75 response, no rebound, and broad applicability in resistant patients.
Pipeline Expansion: HS and asthma trials planned; ITK inhibition shows potential for multiple inflammatory diseases.
PTCL Momentum: Phase III trial progressing with interim analysis expected in 2026.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Corvus (CRVS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Corvus (CRVS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Corvus (CRVS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Corvus (CRVS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown